My bad, appears to be true, but no reimbursement.
AVH.....
Following FDA approval, we conducted a post-market study and initiated a health economics study to capture the
longitudinal healthcare costs for a vitiligo patient. Both studies were submitted for publication in 2024. In early 2025, we expect these
studies to be published, which will support the possible reimbursement necessary for the commercialization of the vitiligo indication
Ann: CLINUVEL Unveils Vitiligo Program for AAD 2025, page-51
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$9.82 |
Change
-0.010(0.10%) |
Mkt cap ! $496.2M | |||
| Open | High | Low | Value | Volume |
| $9.89 | $9.99 | $9.66 | $468.9K | 47.75K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 161 | $9.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.83 | 131 | 9 |
View Market Depth
| Last trade - 12.38pm 16/06/2025 (20 minute delay) ? |
| CUV (ASX) Chart |